Betta Pharmaceuticals Co., Ltd.
SZSE:300558.SZ
56.19 (CNY) • At close October 26, 2023
Overview | Financials
Numbers are in millions (except for per share data and ratios) CNY.
| 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue
| 2,442.13 | 2,376.63 | 2,245.856 | 1,870.266 | 1,553.924 | 1,224.172 | 1,026.359 | 1,035.061 | 914.664 | 704.435 | 480.698 | 312.385 | 62.831 |
| Cost of Revenue
| 565.615 | 268.694 | 174.436 | 138.898 | 105.228 | 68.989 | 43.703 | 32.829 | 27.943 | 24.413 | 21.371 | 21.587 | 10.222 |
| Gross Profit
| 1,876.515 | 2,107.936 | 2,071.419 | 1,731.368 | 1,448.697 | 1,155.183 | 982.655 | 1,002.232 | 886.721 | 680.023 | 459.327 | 290.798 | 52.609 |
| Gross Profit Ratio
| 0.768 | 0.887 | 0.922 | 0.926 | 0.932 | 0.944 | 0.957 | 0.968 | 0.969 | 0.965 | 0.956 | 0.931 | 0.837 |
| Reseach & Development Expenses
| 591.395 | 699.904 | 565.948 | 362.85 | 326.363 | 303.696 | 202.73 | 161.503 | 119.944 | 88.269 | 65.456 | 39.744 | 0 |
| General & Administrative Expenses
| 133.088 | 316.774 | 192.966 | 135.654 | 138.044 | 99.799 | 73.974 | 27.022 | 25.372 | 21.706 | 11.217 | 58.916 | 21.994 |
| Selling & Marketing Expenses
| 853.886 | 779.058 | 814.719 | 684.004 | 562.989 | 496.352 | 393.887 | 398.575 | 337.822 | 251.28 | 171.214 | 120.761 | 27.837 |
| SG&A
| 1,007.339 | 1,095.831 | 1,007.685 | 819.658 | 701.033 | 596.151 | 467.861 | 425.598 | 363.193 | 272.986 | 182.431 | 179.678 | 49.831 |
| Other Expenses
| 1.793 | 103.808 | 116.367 | 106.303 | 109.549 | 1.667 | 69.656 | 58.556 | 40.64 | 17.96 | 17.423 | 17.712 | 18.766 |
| Operating Expenses
| 1,596.941 | 1,899.543 | 1,690 | 1,288.811 | 1,136.946 | 960.868 | 720.098 | 638.666 | 528.36 | 394.094 | 271.776 | 185.517 | 50.582 |
| Operating Income
| 279.574 | 201.784 | 395.6 | 680.667 | 266.564 | 180.706 | 221.002 | 366.372 | 358.115 | 290.561 | 189.287 | 100.826 | -1.062 |
| Operating Income Ratio
| 0.114 | 0.085 | 0.176 | 0.364 | 0.172 | 0.148 | 0.215 | 0.354 | 0.392 | 0.412 | 0.394 | 0.323 | -0.017 |
| Total Other Income Expenses Net
| 56.488 | -114.213 | -5.673 | -14.005 | -0.108 | -11.942 | 28.101 | 60.891 | 40.36 | 22.407 | 18.909 | 12.052 | 15.656 |
| Income Before Tax
| 336.061 | 87.571 | 389.928 | 666.662 | 266.456 | 182.373 | 290.658 | 424.456 | 398.72 | 308.336 | 206.46 | 117.332 | 17.683 |
| Income Before Tax Ratio
| 0.138 | 0.037 | 0.174 | 0.356 | 0.171 | 0.149 | 0.283 | 0.41 | 0.436 | 0.438 | 0.429 | 0.376 | 0.281 |
| Income Tax Expense
| -11.541 | -37.192 | 10.367 | 65.577 | 40.616 | 18.85 | 39.879 | 56.592 | 55.285 | 41.129 | 28.27 | 12.258 | -1.132 |
| Net Income
| 348.032 | 145.42 | 383.068 | 606.361 | 230.822 | 166.818 | 257.727 | 368.796 | 345.298 | 269.286 | 178.399 | 104.899 | 17.557 |
| Net Income Ratio
| 0.143 | 0.061 | 0.171 | 0.324 | 0.149 | 0.136 | 0.251 | 0.356 | 0.378 | 0.382 | 0.371 | 0.336 | 0.279 |
| EPS
| 0.83 | 0.35 | 0.92 | 1.5 | 0.58 | 0.42 | 0.64 | 1.01 | 0.96 | 0.75 | 0.5 | 1.85 | 0.049 |
| EPS Diluted
| 0.83 | 0.35 | 0.92 | 1.49 | 0.57 | 0.42 | 0.64 | 1.01 | 0.96 | 0.75 | 0.5 | 1.85 | 0.049 |
| EBITDA
| 583.061 | 455.485 | 579.732 | 873.631 | 457.351 | 307.899 | 361.388 | 448.601 | 418.373 | 326.311 | 221.82 | 106.648 | 2.015 |
| EBITDA Ratio
| 0.239 | 0.192 | 0.258 | 0.467 | 0.294 | 0.252 | 0.352 | 0.433 | 0.457 | 0.463 | 0.461 | 0.341 | 0.032 |